Acelyrin

Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights.

Third Harmonic Bio stockholders overwhelmingly approved a liquidation and dissolution plan with 99.9% of voting shares supporting the proposal at the June 5, 2025 annual meeting.

• Alumis and Acelyrin have entered into a merger agreement, marking a significant consolidation in the biotechnology sector. • The companies announced the suspension of the planned Phase III program for lonigutamab following disappointing Phase II results reported in January. • The merger decision includes a strategic reassessment of lonigutamab's development program to evaluate its potential value and future direction.

Alumis and Acelyrin have agreed to merge in an all-stock transaction, creating a combined entity with $737 million in cash runway extending into 2027.

• Acelyrin's lonigutamab Phase 1/2 study update reveals that lower doses administered every four weeks were subtherapeutic for thyroid eye disease (TED). • The company's analysis determined that a minimum concentration of 3 ug/ml is required for maximized efficacy, achievable with a 100 mg loading dose followed by 50 mg every two weeks. • Phase 3 program for lonigutamab in TED is set to begin in the first quarter of 2025, utilizing the optimized dosing regimen based on pharmacokinetic data. • H.C. Wainwright adjusted Acelyrin's stock target to $6.00, maintaining a Neutral rating, reflecting the Phase 1/2 study findings and future trial design.

• Acelyrin's lonigutamab demonstrates a potential best-in-class efficacy and safety profile for treating Thyroid Eye Disease (TED), according to updated Phase 2 data. • A virtual investor event on January 6, 2025, will feature clinician perspectives on unmet needs in TED and the design of the Phase 3 LONGITUDE program. • The Phase 3 LONGITUDE program, developed after discussions with the FDA, aims to be the most inclusive registrational program in TED to date. • Lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, offers potential for longer-term, convenient dosing, improving clinical response.

• Acelyrin will present Phase 2 data for subcutaneous Lonigutamab, indicating a potentially best-in-class efficacy and safety profile for Thyroid Eye Disease (TED). • The company plans to unveil the design for its Phase 3 program following a successful meeting with the FDA. • A virtual investor event is scheduled to reveal the data and Phase 3 design, featuring experts from Stanford and the University of Colorado School of Medicine.

Acelyrin Inc. (SLRN) stock reached a 52-week low amidst challenging market conditions, reflecting broader economic pressures and investor concerns.

• Acelyrin's lead drug candidate, Izokibep, is currently in Phase 3 clinical trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and Phase 2 trials for Axial Spondyloarthritis. • Institutional investors, including Point72 Asset Management L.P., have increased their positions in Acelyrin, indicating confidence in the company's potential. • Several analysts have adjusted their price targets for Acelyrin, reflecting evolving expectations for the company's performance and the potential of Izokibep. • Acelyrin's stock experienced trading fluctuations, highlighting the dynamic nature of the biopharmaceutical market and investor sentiment towards the company.

• Acelyrin's Phase 2b/3 trial of izokibep (izo) in uveitis has failed, leading to the removal of its contribution from Wells Fargo's financial model. • Wells Fargo has lowered its price target for Acelyrin from $15 to $13, while maintaining an Overweight rating on the shares. • The firm believes the downside impact on Acelyrin's stock will be limited due to the market not assigning significant value to the uveitis program.